Table 7. The effect of quarterly albendazole during childhood on incidence of malaria, diarrhoea, pneumonia, and eczema (15 months to 5 years).

		Albendazole Placebo	Albendazole
Malaria	Events (pyrs at risk ×100)	1006 (31.67)	845 (31.11)
	Rate per 100 pyrs	31.77	27.16
	Hazard ratio (95% CI)		0.85 (0.73–0.98)
	P value		0.03
Diarrhoea	Events (pyrs at risk ×100)	1173 (31.59)	1147 (30.97)
	Rate per 100 pyrs	37.13	37.04
	Hazard ratio (95% CI)		0.99 (0.88–1.11)
	P value		0.84
Pneumonia	Events (pyrs at risk ×100)	211 (31.97)	206 (31.35)
	Rate per 100 pyrs	6.60	6.57
	Hazard ratio (95% CI)		0.99 (0.76–1.28)
	P value		0.92
Eczema	Events (pyrs at risk ×100)	77 (32.03)	107 (31.39)
	Rate per 100 pyrs	2.40	3.41
	Hazard ratio (95% CI)		1.25 (0.78–2.01)*
	P value		0.36

^*Hazard Ratio adjusted for eczema prior to randomisation and maternal hookworm at enrolment.